Compile Data Set for Download or QSAR
Report error Found 66 Enz. Inhib. hit(s) with all data for entry = 11826
TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651653(US20240051936, Compound 59)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651648(US20240051936, Compound 54)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651647(US20240051936, Compound 53)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651646(US20240051936, Compound 52)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651650(US20240051936, Compound 56)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651613(US20240051936, Compound 19)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651611(US20240051936, Compound 17)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651651(US20240051936, Compound 57)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651652(US20240051936, Compound 58)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651654(US20240051936, Compound 60)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651605(US20240051936, Compound 11)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651631(US20240051936, Compound 37)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651656(US20240051936, Compound 62)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651632(US20240051936, Compound 38)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651634(US20240051936, Compound 40)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651638(US20240051936, Compound 44)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651660(US20240051936, Compound 73)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651640(US20240051936, Compound 46)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651639(US20240051936, Compound 45)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651641(US20240051936, Compound 47)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651643(US20240051936, Compound 49)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651644(US20240051936, Compound 50)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651645(US20240051936, Compound 51)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651636(US20240051936, Compound 42)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651637(US20240051936, Compound 43)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651599(US20240051936, Compound 5)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651649(US20240051936, Compound 55)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651617(US20240051936, Compound 23)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651614(US20240051936, Compound 20)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651610(US20240051936, Compound 16)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651621(US20240051936, Compound 27)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651635(US20240051936, Compound 41)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651633(US20240051936, Compound 39)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651601(US20240051936, Compound 7)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651603(US20240051936, Compound 9)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651630(US20240051936, Compound 36)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651642(US20240051936, Compound 48)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651612(US20240051936, Compound 18)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651615(US20240051936, Compound 21)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651620(US20240051936, Compound 26)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651655(US20240051936, Compound 61)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651657(US20240051936, Compound 70)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651658(US20240051936, Compound 71)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651659(US20240051936, Compound 72)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651628(US20240051936, Compound 34)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651616(US20240051936, Compound 22)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651596(US20240051936, Compound 2)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651597(US20240051936, Compound 3)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651598(US20240051936, Compound 4)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM651600(US20240051936, Compound 6)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 66 total ) | Next | Last >>
Jump to: